1189105-79-0 Usage
Description
Ethyl 7-bromo-4-chloroquinazoline-2-carboxylate is a chemical compound with the molecular formula C12H10BrClN2O2. It belongs to the class of organic compounds known as quinazoline carboxylic acids and derivatives. Ethyl 7-bromo-4-chloroquinazoline-2-carboxylate is characterized by its unique structure, which includes a quinazoline core with a bromine atom at the 7th position and a chlorine atom at the 4th position, as well as an ethyl ester group at the 2nd position. Its properties and structure make it useful in the development of new medications for a variety of medical conditions.
Uses
Used in Pharmaceutical Industry:
Ethyl 7-bromo-4-chloroquinazoline-2-carboxylate is used as an intermediate in the synthesis of various drugs and pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new medications for a range of medical conditions.
Used in Medicinal Chemistry Research:
Due to its potential applications in drug development, research and development activities for Ethyl 7-bromo-4-chloroquinazoline-2-carboxylate are ongoing. It is considered to be of significant interest in the field of medicinal chemistry, as its structure and properties can be further explored and modified to create novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1189105-79-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,8,9,1,0 and 5 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1189105-79:
(9*1)+(8*1)+(7*8)+(6*9)+(5*1)+(4*0)+(3*5)+(2*7)+(1*9)=170
170 % 10 = 0
So 1189105-79-0 is a valid CAS Registry Number.
1189105-79-0Relevant articles and documents
ADENOSINE A3 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF
-
, (2012/03/12)
Provided herein is a method of preventing, treating, or ameliorating one or more symptoms of an adenosine A3-mediated condition, disorder, or disease, with a compound of Formula I. Also provided herein is a method of preventing, treating, or ameliorating one or more symptoms of glaucoma or ocular hypertension. Further provided herein is a method of modulating the activity of an adenosine A3 receptor.
